RAU-SED Drug Patent Profile
✉ Email this page to a colleague
When do Rau-sed patents expire, and when can generic versions of Rau-sed launch?
Rau-sed is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in RAU-SED is reserpine. There is one drug master file entry for this compound. Additional details are available on the reserpine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RAU-SED?
- What are the global sales for RAU-SED?
- What is Average Wholesale Price for RAU-SED?
Summary for RAU-SED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 99 |
| Patent Applications: | 1,637 |
| DailyMed Link: | RAU-SED at DailyMed |
US Patents and Regulatory Information for RAU-SED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | RAU-SED | reserpine | TABLET;ORAL | 009357-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | RAU-SED | reserpine | TABLET;ORAL | 009357-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | RAU-SED | reserpine | TABLET;ORAL | 009357-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
